BCTX — Briacell Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $34.90m
- $33.69m
2019 July 31st | 2020 July 31st | R2021 July 31st | 2022 July 31st | 2023 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | fx Final | fx Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4.7 | 3.58 | 7.11 | 15.3 | 23.3 |
Operating Profit | -4.7 | -3.58 | -7.11 | -15.3 | -23.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.37 | -3.67 | -13.8 | -26.8 | -20.3 |
Net Income After Taxes | -4.37 | -3.67 | -13.8 | -26.8 | -20.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.37 | -3.67 | -13.8 | -26.8 | -20.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.37 | -3.67 | -13.8 | -26.8 | -20.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.55 | -5.18 | -3.03 | -1.73 | -1.3 |